Mayo Clinic Research on the Effects of EMBP on Post-COVID Syndrome
About Mayo Clinic
Mayo Clinic is a globally renowned medical institution known for its excellence in medical research and innovative treatment methods. Founded in the late 19th century, its headquarters are in Minnesota, USA, with multiple branches across the country. Mayo Clinic has a team of world-class medical experts dedicated to providing personalized treatment solutions and achieving groundbreaking advancements in various medical fields.
In neurology and rehabilitation therapy, Mayo Clinic has long invested in advanced technology and clinical research, particularly in the development of transcranial magnetic stimulation (TMS). TMS is a non-invasive brain stimulation technique commonly used to treat depression, anxiety, and neurological disorders such as Parkinson’s disease and post-stroke recovery.
Research: EMBP Improves Post-COVID Syndrome (PCS)
Following the COVID-19 pandemic, many patients, even after recovery, continue to suffer from Post-COVID Syndrome (PCS), experiencing symptoms such as fatigue, brain fog, memory decline, anxiety, and sleep disturbances. These persistent health issues significantly impact patients' quality of life, creating an urgent need for new treatment options.
To explore potential solutions, Mayo Clinic is conducting a clinical study to evaluate whether EMBP technology can provide objective improvements for PCS patients. The official study title is "Post COVID-19 Syndrome Treatment with Variable Pulse Transcranial Magnetic Stimulation", with study ID 22-011546. For more details, refer to the study plan.
Study Method and Treatment Plan
This study involves PCS patients undergoing treatment using the Electromagnetic Brain Pulse Variable Pulse Protocol (EMBP). Participants are divided into two groups:
- 2-Week Treatment Group: Receives EMBP treatment for two weeks.
- 4-Week Treatment Group: Receives EMBP treatment for four weeks.
The primary objective of the study is to assess symptom improvements after treatment, including cognitive function, emotional state, and physical fatigue. The research team will objectively analyze the efficacy of EMBP through EEG, clinical questionnaires, and physiological measurements.
Potential of EMBP Technology
Compared to traditional TMS, EMBP can adjust pulse patterns based on the patient’s brain response, enhancing treatment precision and personalization. Previous studies have demonstrated that TMS is highly effective in treating depression and neurological damage. The Mayo Clinic research team hopes that EMBP technology will provide a new treatment option for patients with Post-COVID Syndrome.
Research Outlook and Clinical Applications
If this study confirms that variable pulse EMBP is effective for Post-COVID Syndrome, it will bring hope to millions of affected patients and may lead to the widespread clinical adoption of this technology. Mayo Clinic also plans to promote the study results to other medical institutions for further validation of EMBP’s clinical value.
Currently, the research is ongoing. Mayo Clinic will release detailed data upon completion of the study and explore EMBP’s potential applications in other neurological disorders.
Source: NCT06865222 - Post COVID-19 Syndrome Treatment with Variable Pulse Transcranial Magnetic Stimulation https://clinicaltrials.gov/study/NCT06865222
*This information is for reference only. Actual treatment plans should be determined by medical professionals.*
About Mayo Clinic
Mayo Clinic is a globally renowned medical institution known for its excellence in medical research and innovative treatment methods. Founded in the late 19th century, its headquarters are in Minnesota, USA, with multiple branches across the country. Mayo Clinic has a team of world-class medical experts dedicated to providing personalized treatment solutions and achieving groundbreaking advancements in various medical fields.
In neurology and rehabilitation therapy, Mayo Clinic has long invested in advanced technology and clinical research, particularly in the development of transcranial magnetic stimulation (TMS). TMS is a non-invasive brain stimulation technique commonly used to treat depression, anxiety, and neurological disorders such as Parkinson’s disease and post-stroke recovery.
Research: EMBP Improves Post-COVID Syndrome (PCS)
Following the COVID-19 pandemic, many patients, even after recovery, continue to suffer from Post-COVID Syndrome (PCS), experiencing symptoms such as fatigue, brain fog, memory decline, anxiety, and sleep disturbances. These persistent health issues significantly impact patients' quality of life, creating an urgent need for new treatment options.
To explore potential solutions, Mayo Clinic is conducting a clinical study to evaluate whether EMBP technology can provide objective improvements for PCS patients. The official study title is "Post COVID-19 Syndrome Treatment with Variable Pulse Transcranial Magnetic Stimulation", with study ID 22-011546. For more details, refer to the study plan.
Study Method and Treatment Plan
This study involves PCS patients undergoing treatment using the Electromagnetic Brain Pulse Variable Pulse Protocol (EMBP). Participants are divided into two groups:
- 2-Week Treatment Group: Receives EMBP treatment for two weeks.
- 4-Week Treatment Group: Receives EMBP treatment for four weeks.
The primary objective of the study is to assess symptom improvements after treatment, including cognitive function, emotional state, and physical fatigue. The research team will objectively analyze the efficacy of EMBP through EEG, clinical questionnaires, and physiological measurements.
Potential of EMBP Technology
Compared to traditional TMS, EMBP can adjust pulse patterns based on the patient’s brain response, enhancing treatment precision and personalization. Previous studies have demonstrated that TMS is highly effective in treating depression and neurological damage. The Mayo Clinic research team hopes that EMBP technology will provide a new treatment option for patients with Post-COVID Syndrome.
Research Outlook and Clinical Applications
If this study confirms that variable pulse EMBP is effective for Post-COVID Syndrome, it will bring hope to millions of affected patients and may lead to the widespread clinical adoption of this technology. Mayo Clinic also plans to promote the study results to other medical institutions for further validation of EMBP’s clinical value.
Currently, the research is ongoing. Mayo Clinic will release detailed data upon completion of the study and explore EMBP’s potential applications in other neurological disorders.
Source: NCT06865222 - Post COVID-19 Syndrome Treatment with Variable Pulse Transcranial Magnetic Stimulation https://clinicaltrials.gov/study/NCT06865222
*This information is for reference only. Actual treatment plans should be determined by medical professionals.*